x

Búsqueda de un ensayo clínico

* (*) Campo obligatorio

158 Resultado(s)

Ordenados por

Ensayo clínico en reclutamiento = Ensayo clínico en reclutamiento
; Ensayos clínico en curso = Ensayos clínico en curso 
; Financiado por un miembro del IRDiRC =

Ensayo(s) clínico(s) nacional(es)

ALEMANIA

Sachsen
DRESDEN

ALEMANIA

Sachsen
DRESDEN

Ensayo clínico en reclutamiento
Ensayos clínico en curso 
RELAZA2 (TUD-RELA02-048): Treatment of patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) with an impending hematological relapse with Azacitidin (Phase II)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALEMANIA

Baden-Württemberg
FREIBURG

ALEMANIA

Baden-Württemberg
FREIBURG

Phase III study of low-dose intravenous decitabine in patients aged > 60 years with acute myeloid leukemia who are not eligible for standard induction chemotherapy - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation

ALEMANIA

Baden-Württemberg
HEIDELBERG

ALEMANIA

Baden-Württemberg
HEIDELBERG

Phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

ALEMANIA

Baden-Württemberg
TÜBINGEN

Ensayo clínico en reclutamiento
Ensayos clínico en curso 
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

ALEMANIA

Berlin
BERLIN

WT1 Vaccination: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML - DE
Charité - Universitätsmedizin Berlin (CCM)
Charité Comprehensive Cancer Center (CCCC)

ALEMANIA

Niedersachsen
HANNOVER

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie

ALEMANIA

Niedersachsen
HANNOVER

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III) - DE
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation

ALEMANIA

Nordrhein-Westfalen
ESSEN

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

ALEMANIA

Nordrhein-Westfalen
LEVERKUSEN

CP4055-205: A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with Acute Myeloid Leukaemia (AML) - DE
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

ALEMANIA

Sachsen
DRESDEN

Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALEMANIA

Sachsen
DRESDEN

TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALEMANIA

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

ALEMANIA

Thüringen
JENA

Phase II study of Cladribine, high-dose Cytarabine and Idarubicin in patients with relapsed acute myeloid leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

DINAMARCA

Jylland
AARHUS

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics

ESPAÑA

Comunidad Valenciana
VALENCIA

APL-R2007: Tratamiento de la recaída en leucemia promielocítica con trióxido de arsénico (Fase IV) (completado)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

ESPAÑA

Comunidad Valenciana
VALENCIA

ESPAÑA

Madrid
MADRID

ESPAÑA

Madrid
MADRID

APL-R2007: Tratamiento de la recaída en leucemia promielocítica con trióxido de arsénico (Fase IV) (completado)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia

ESPAÑA

Madrid
MADRID

PETHEMA-LAM99: Tratamiento de la leucemia mieloblástica aguda en pacientes mayores de 65 años (Fase IV) (completado)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia

FRANCIA

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANCIA

AUVERGNE-RHONE-ALPES
LYON

CLARA-DNX : A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
CHU de Lyon HCL - GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse

FRANCIA

ILE-DE-FRANCE
BOBIGNY

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III)
CHU Paris Seine-Saint-Denis - Hôpital Avicenne
Service d'hématologie clinique

FRANCIA

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Maladies du sang

FRANCIA

OCCITANIE
MONTPELLIER

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Acute Myeloid Leukemia - Terminated -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

ITALIA

FRIULI VENEZIA GIULIA
UDINE

ITALIA

LAZIO
ROMA

Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
Azienda Ospedaliera Universitaria Policlinico di Tor Vergata
U.O.C. Ematologia

PAISES BAJOS (LOS)

Gelderland
NIJMEGEN

REINO UNIDO (EL)

South Glamorgan
CARDIFF

Ensayos clínico en curso 
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REINO UNIDO (EL)

South Glamorgan
CARDIFF

Ensayo clínico en reclutamiento
Ensayos clínico en curso 
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REINO UNIDO (EL)

South Glamorgan
CARDIFF

AML 15: Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REINO UNIDO (EL)

South Glamorgan
CARDIFF

AML-HR: Protocol for patients with high risk (resistant, refractory, relapsed or adverse cytogenetic) AML (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REINO UNIDO (EL)

Greater Manchester
ADDRESS: NOT PROVIDED - UK

Ensayo(s) clínico(s) multinacional(es)

ESTADOS UNIDOS

New Jersey
RARITAN